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Drugs Most Frequently Used in Office-Based Practice: 
NationalAmbulatory Medical Care Survey, 1980 
by Hugo Koch, Division of Health Care Statistics 
. This report lists and describes the 200 drugs most 
frequently utilized in 1980 by physicians engaged in 
office-based practice. (Inclusion of trade names is for 
identification only and does not imply endorsement 
by the Public Health Service or the U.S. Department 
of Health and Human Services.) Data are based on 
findings from the National Ambulatory Medical Care 
Survey. 
The National Center for Health Statistics uses the 
National Ambulatory Medical Care Survey (NAMCS) 
to collect descriptive data about the medical care pro­
vided in doctors’ offices. Each year NAMCS data col­
lectors contact a representative sample of the 
Nation’s doctors of medicine and osteopathy whose 
primary jobs are office-based, patient-care practice. 
The sampled physicians in turn complete records 
(figure 1) for a systematic random sample of their 
office visits over a weekly reporting period. 
The year 1980 was the first in the 8-year history 
of NAMCS that respondents reported the number and 
names of the specific drugs they used (see figure 1, 
item 11). This resulted in an estimated 679,593,000 
mentions of pharmaceutical agents ordered or pro­
vided for the purpose of prevention, diagnosis, or 
treatment. Mentions included new or continued medi­
cations and nonprescription as well as prescription 
drugs. The methodology used to collect and process 
drug information for the 1980 NAMCS is reported 
elsewhere. 1 
Since the estimates presented in this report are 
based on a sample rather than on the entire universe 
of office visits, the data are subject to sampling vari­
ability. The technical notes at the end of this report 
provide a brief explanation of the sampling errors, 
and guidelines for judging the precision of estimates. 
Table 1 lists, in rank order, the 200 drugs that 
lNational Center for Health Statistics, H. Koch: The collection and 
processing of drug information, National Ambulatory Medical Care 
Survey, United States, 1980. Vital and Health Statistics. Series 2-No. 
90. DHHS Pub. No. (PHS) 82-1364. Public Health Service. Washing-
ton. U.S. Government Printing Office. In press. 
physicians most frequently ordered or provided at 
their office visits. The listing is arbitrarily restricted 
to the mentions of drugs that were specifically named 
by respondents. This led to the exclusion of four 
entry choices that did not identify a specific agent, 
indicating only the therapeutic effect desired. These 
four therapeutic effects were: 
�	 Allergy relief or shots (unspecified), with 
9,986,000 mentions. 
�	 Vitamin(s) (unspecified), with 2,124,000 men­
tions. 
�	 Vawination (unspecij7ed), with 1,233,000 men­
tions. 
� Skin preparations (unspecified), with 948,000 
mentions. 
A superscript following a listed drug indicates a 
drug family; i.e., a grouping of drugs whose members 
have the same core identifier and the same or a 
closely similar therapeutic effect. Example: the drug 
family ARISTOCORTf includes the following mem­
bers: ARISTOCORT, ARISTOCORT A, ARISTO­
CORT FORTE, ARISTOCORT HP, ARISTOCORT 
INTRALESIONAL, and ARISTOCORT R. 
The reader is cautioned that these rankings, due 
to sampling variability, may be somewhat artificial 
because some estimates may not enjoy a clear statisti­
cal difference from other near estimates. 
The 200 drugs comprise only 8 percent of the 
total 2,632 drugs named by respondents. However, 
they accounted for about 448,707,000 mentions, or 
66 percent of the total 679,593,000 drug mentions. 
Tables 2, 3, 4, 5, and 6 characterize the 1980 
drug mentions according to certain key dimensions, 
the knowledge of which is basic to any study of drug 
utilization. From these tables the reader may judge 
the degree that the ranking 200 drugs are representa­
tive of all drug mentions. 
Entry status. –The data in table 2 characterize the 
drug mentions by their entry status; that is, they re-
veal whether the doctor recorded the mention by 
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Table 1. The 200 drugs most frequently used in office-based practice, by name of drug, generic class, and number of mentions: 
United States, 1980 
Rank Name of drugq 
Ali drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
200 drugs most frequently used 
LAslx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
AMPICILLIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
PENICILLINf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
INDERAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
TETRACYCLINEf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
ASPIRINf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
DYAZIDE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
LANOXIN . . . . . . . . . . . . . . . . .)....... . . . . . . . . . . . . . . . . 
POLIO VACCINE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
VALIUM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
DIPHTHERIA TETANUSTOXOIDS PERTUSSIS . . . . . . . . . . . . . . 
PREDNISONE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
MOTRIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
vlTAMIN B-12f . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
HYDROCHLOROTHIAZIDEf . . . . . . . . . . . . . . . . . . . . . . . . . . . 
AMOXICILLIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
DIMETAPP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
ERYTHROMYCIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
INSULIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
TYLENOL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
HYGROTON . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
TYLENOLW/CODEINEf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
PHENERGANf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
CLINORIL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
BENADRYL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
AMOXIL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
KENALOG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
DIA81NESE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
INDOCIN . ; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
NITROGLYCERIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
THYROID . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
DARVOCET-N . . . . . . . . . . . . . .’ . . . . . . . . . . . .
. ?.. . . . . . . . 
CORTISPORIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
BACTRIMf . . . . . . . . ...’..... . . . . . . . . . . . . . . . . . . . . . . . . 
CLEOCINf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
NAPROSYN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
E-MYCIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
DIMETANEf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
PHENERGANW/CODEINEf . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
SEPTRAf, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
PREMARINf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
LOPRESSOR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
DONNATAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
DECADRONf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
NEOSPORIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
ELAVIL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
ALDACTAZIDE 
influenza VlRilSVA6ClNE:: :::::::::::::::::::::::: 
TRANXENE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
DALMANE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
POTASSIUM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
ALDORIL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
COUMADIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
: SYNTHROID . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
See footnote at end of table. 
DIOXIN . . . . . . . . . . . 
TUBERCULIN TINE TEST’ 
TAGAMET . . . . . . . . . . 
HYDRODIURIL . . . . . . . 
KEFLEX . . . . . . . . . . . 
E.E.S. . . . . . . . . . . . . . . 
ACTIFED . . . . . . . . . . . 
ISORDIL . . . . . . . . . . . 
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Tablel. The200drugs most frequently used inoffice-based practice, bynameof drug, generic class, and number of mentions: 
United States, 1980–Con. 
Number of 
Rank Name of drug’1 
64 DIURIL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

65 ANTIVERT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

66 PRENATAL VITAMINSf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

67 BUTAZOLIDINf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

68 MONISTATf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

69 CELESTONEf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

70 SLOW-K . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

71 PEN-VEE-K . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

72 V-CILLINf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

73 XYLOCAINEf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

74 DILANTIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

75 TIMOPTIC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

76 VIBRAMYCIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

77 PHENOBARBITAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

78 SINEQUAN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

79 MINOCIN, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

80 DEPO-MEDROL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

81 ATARAX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

82 HYDROCORTISONE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

83 MACRODANTIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .,

84 ORTHO-NOVUM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

85 EMPIRINW/CODEINEf, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

B6 LIBRA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

87 DRIXORAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

88 MYCOLOG Y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

89 NALFON . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

90 81clLLlNf . . . . . . . . . . . . . ...’-. . . . . . . . . . . . . . . . . . . . . . . .

91 ROBITUSSINf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

92 LOMOTIL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

93 FLUOROURACIL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

94 PERSANTINE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .





97 TETANUS+OX’ODD::::::::: ::::::::::::::::::::::: ::

98 CHORIONICGONADOTROPIN . . . . . . . . . . . . . . . . . . . . . . . . . .

99 CHLOR-TRIMETONf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

100 NOVAHISTINEf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

101 CAROTID . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

102 ORNATE . . . . . . . . ...’..... . . . . . . . . . . . . . . . . . . . . . . . . .

103 ARISTOCORTf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

104 ATIVAN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .





107 SUDAFEDf . . . . . . . . . . . . . . ::::::::::::::::::::::: :::

108 COM81D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

109 FIORINAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

110 NITRO-BID . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

111 MAALOX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

112 ASCRIPTIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

113 LIDEX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

114 ORINASE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

115 APRESOLINE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...”.. . . .





118 GANTRklN” :::::::::::::: ::::::::::::::::::::::: ::

119 ZYLOPRIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

120 SER-AP-ESf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

121 TRIAVIL, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

122 ESIDRIX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

123 ILOSONE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

124 BRETHINE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

125 ENDURON, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

126 LO/OVRAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

127 MELLARIL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

128 RONDECf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

129 NORGESIC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

See footnote at end of table, 
















































































































































































































Name of drug 1 
VALISONE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
TERRAMYCIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
RETIN-A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
PARAFON FORTE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
RESERPINE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
M-M-R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
DIPHTHERIA TETANUSTOXOIDS . . . . . . . . . . . . . . . . . . . . . . . 
NALDECON . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
MAXITROL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
METAMUCIL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
ROBAXIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
MINIPRESS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
BENTYL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
IONAMIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
QUINIDINEf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
PERCODANf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
DARVONf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
CORTISONE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
THEO-DUR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
FLAGYL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
DIPROSONE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
METHOTREXATE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
ESTROGEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
CYTOXAN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
FASTIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
TOLECTIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
LINCOCIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
TRIAMINICf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
NEO-SYNEPHRINEf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
PILOCARPINE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
ALUPENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
ORAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
FLURESS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
SOMAf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
MEPROBAMATE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
CHLOROPTICf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
TITAN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
MYCOSTATIN 
ZAROXOLYN .::::::::::::: :::::::::::::::::::::::: 
TUSS-ORNADE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
DONNAGELf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
SALICYLICACIDf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
DESQUAM-Xf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
NITROGEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
LIMBITROL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
CORDRANf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
BENYLIN SYRUP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
LOTRIMIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
8ETADlNEf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
CATAPRES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
AMINOPHYLLINEf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
CORGARD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
QUIBRONf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
DEMEROL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
FLEXERIL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
IRON PREPARATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
SORBITRATE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
TOLINASE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
8ENzAcf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
TOFRANIL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
MEDROL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
FERROUSSULFATE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
ERYTHROCIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
PAVABID . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
DRAMAMINE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
SLO-PHYLLINf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Number of 
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Tablel. The200drugs mow frequently used inoffice-based practice, bynameof drug, generic class, and number of mentions: 
United States, 1980-Con. 
Number of 
Rank Name of drug 1 Generic class mentions in 
thousands 
196 VASODILAN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ISOXUPRINE 818 
197 TOPICORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . DESOXIMETASONE 805 
198 COMPAZINE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . PROCHLORPERAZINE 782 
199 VELOSEF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CEPHRADINE 781 
200 ITALWINf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . PENTAZOCINE 779 
Isuperscriptf denotes drug familY. 
Table2. Number andpercent distribution ofalldrug mansions, andnum&r, percent distribution, andpercent ofalldrug mentions of the200 drugs 
most frequently named, byentrystatux United States, 1980 
All drugs 200 drugs most frequently 
named 
Entry status Numberof Numberof Percent of 
mentions Percant mentions Percent 
all drug
iJ7 distribution in distribution 
mentions 
thousands thousands 
Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 679,593 100.0 448,707 100.0 66.0 
Generic name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164,464 24.2 128,501 28.6 78,1 
Brandname . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 483,587 71.2 320,206 71.4 66.2 
Unknown . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31,542 4.6 . . . . . . ,,. 
* 
Table3. Number andpercent distribution ofalldrug mentions, andnumber, percant distribution, andparcent ofalldrug mentions of the200 drugs 
most frequently named, by prescription status: United States, 1980 
All drugs 200 drugs most frequently 
named 
Prescription status Numberof Numberof Percent of 
mentions Percent mentions Percent 
all drug
in distribution in distribution 
mantions 
thousands thousands 
Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 679,593 100.0 448,707 100.0 66.0 
Prescriptiondrug . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 561,228 82.6 403,807 90.0 72.0 
Nonprescription drug . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85,344 12.6 44,900 10,0 52,6 
Unknown . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33,021 4.9 . . . . . . . . . 
ackEdab7 
Table4. Number andpercent distribution of alldrug mentions, andnumber, percent distribution, and percent of alldrug mentions of the200 drugs 
most frequently named, by Fecferal control status: United States, 1980 
All drugs 200 drugs most frequently 
named 
Federal control status Number of Number of Percent of 
men tions Percent mentions Percent 
alt drug
in distribution in distribution 
mentions 
thousands thousands 
Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 679,593 100.0 448,707 100.0 66.0 
Controlled by DEAD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58,550 8.6 40,076 8.9 68.4 
Schedule 11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,763 0.8 1,984 0.4 34.4 
Schedule ill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12,037 1.8 6,750 1.5 56.1 
Schedule IV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30,305 4.5 22,228 5.0 73.3 
Schedule V . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10,445 1.5 9,114 2.0 87.3 
Uncontrolled . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 588,022 86.5 408,631 91.1 69.5 
Unknown . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33,021 4.9 . . . . . . . . . 
IDrug Enforcement Administration. 
Table5. Number andpercent distribution ofalldrug mentions, andnum&r, percent distribution, andpercent ofalldrug mentions of the200 drug 
most frequently named, by composition status: United States, 1980 
All drugs 200 drugs most frequently 
named 










Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 679,593. 100.0 44.8,707 “100.0 66.0 
Single-ingredient drug . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 468,752 69.0 348,294 77.6 74.3 
Combination drug . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165,798 24.4 96,840 21.6 58.4 
Multivitamins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13,500 2,0 3,573 0.8 26.5 
Unknown . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31,542 4.6 . . . . . . . . . 
8 
Table6. Number andpercent distribution ofalldrug mentions, andnumber, percent distribution, andpercent ofalldrug mentions of the200 drug 
most frequently named, by therapeutic category: United States, 1980 
All drugs 200 drugs most frequently 
named 




Number of Parcent of
mentions Percent all drugin distribution 
mentions
thousands 
All categories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 679,593 100.0 448,707 100.0 66.0 
Antihistamine drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43,939 6.6 26,269 5.9 59.8 
Anti-infective agents (nontopical) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104,898 15.4 84,046 18.7 80.1 
Antibiotics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90,081 13.3 75,526 16.8 83.8 
Antineoplastic agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,371 0.8 3,683 0.8 68.6 
. 
Autonomicdrugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25,237 3.7 13,653 3.0 54.1 
Bloodformation andcoagulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8,312 1.2 2,840 0.7 35.4 
Cardiovasculardrugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64,463 9.5 52,010 11.6 80.7 
Cardiacdrugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26,331 3.9 24,397 5.4 92.7 
Hypotensiveagents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22.633 3.3 15,848 3.5 70.0 
Vasodilatingagents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14;646 2.2 11,765 2.6 80.3 
Central nervoussystemdrugs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110,706 16.3 80,271 17.9 72.5 
Analgesics andantipyretics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57,800 8.5 47,408 10.6 82.0 
Psychotherapeuticagents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16,395 2.4 9,195 2.0 56.1 
Sedativesand hypnotics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25,036 3.7 19,671 4.4 78.6 
Diagnoaticagents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,673 0.7 4,488 1.0 96.0 
Electrolytic,caloric, and water balance . . . . . . . . . . . . . . . . . . . . . . . . 51,956 7.6 43,186 9.6 83.1 
Diuretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42,834 6.3 39,074 8.7 91.2 
Expectorantsand coughpreparations . . . . . . . . . . . . . . . . . . . . . . . . . . 18,899 2.8 8,881 2.0 47.0 
Eye,ear, nose,and throat preparations . . . . . . . . . . . . . . . . . . . . . . . . . 26,076 3.8 10,798 2.4 41.4 
Gastrointestinal drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24,140 3.6 15,029 3.3 62.3 
Hormonesandsynthetics ubstances . . . . . . . . . . . . . . . . . . . . . . . . . . . 55,843 8.2 41,781 9.3 74.8 
Adrenals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18,312 2.7 15,425 3.4 84.2 
Serums, toxoids,andvaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23,711 3.5 18,747 4.2 79.1 
Skin and mucous membrane preparations . . . . . . . . . . . . . . . . . . . . . . . 55,188 8.1 25,783 5.7 46.7 
Spasmolyticagents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11,541 1.7 4,494 1.0 38.9 
Vitamins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24,244 3.6 9,386 2.1 38.7 
Otheragents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10,378 1.5 3,262 0.7 31.4 
Undetermined . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10,017 1.5 
lBa~edon thepharmacologic-therapeuticclassification of tha Amarican Society of Hospital Pharmacists. 
brand name orby generic name. (Note: NAMCSre­
spondents were instructed to use the same entry 
statuson the NAMCSvisit record (figure l) that they 
used on the patient’s medical record and/oron any 
prescription written.) 
Extensive discussion has occurred during thepast 
decade about the costs and merits of prescribingby 
brand name versus the usually less costly generic 
name. Since 1970, the generic drug business has 
grown faster than the total pharmaceutical market. 
To cite one study: “While the market expandedby 
10 percent from 1977 to 1979,genericsgrew by12.6 
percent during that period. By 1979, 14percent ofall 
new prescriptions written by physicians were for 
generic drugs, up from 7 percentin 1970.”2 
It should be emphasized that the extent of 
generic utilization revealed by the NAMCS data in 
table 2 (24 percent of all drugs mentioned-29 per-
cent of the leading 200) reflects the total utilization 
of generic drugs in office-based practice. Thus along 
with the generic prescriptions-new ones or refills– 
2Mayer, C. E.: Drug industry war heatsup over generics. Washington 
Post, Dec. 20,1981. pp K1-2. 
that the doctor intended to be filled by a dispensing 
pharmacist, the NAMCS generic fraction includes 
such other agents as: nonprescription generics (e.g., 
ASPIRIN or INSULIN); most serums, toxoids and 
vaccines (e.g., DIPHTHERIA TETANUS TOXOID 
PERTUSSIS); most diagnostic agents (e.g., TUBER­
CULIN); and a substantial number of other agents– 
chiefly antibiotic-injectibles-administered in the doc-
tor’s office. 
—. 
Prescription stat;;.-e ‘d=a- in tare 3 charac­
terize the drug mentions by their Federal legal classi­
fication. These data reveal whether the doctor re-
corded a prescription (Rx) drug or a nonprescription 
(over-the-counter or OTC) drug. The choice of a pre­
scription drug by a prescribing physician indicates 
relatively more judgmental control by the physician 
than does the choice of a nonprescription drug, which 
represents a greater reliance on self-care by the 
patient. Also, OTC drugs are usually less expensive 
than their Rx counterparts. (However, except for 
INSULIN, they are not usually covered as an insured 
benefit in third-party programs.) Thus it is interesting 
to learn from table 3 that at least 13 percent of all 






Federal control status. -A very important issue in 
health and social policy is the use of medications 
having significant potential for addiction or habitua­
tion. Such medications are under the regulatory con­
trol of the Drug Enforcement Administration (DEA), 
an agency of the U.S. Department of Justice. In 
table 4 the medications used in office-based practice 
are characterized by their DEA control level 
(“schedule”). Each successive Schedule, from II 
through V, reflects a decreasing potential for abuse, 
as follows: 
Schedule II (MORPHINE, DEMEROL, AMPHET­
AMINES) High potential for abuse. Abuse may 
lead to severe psychological or physical depend­
ence. 
Schedule III (FIORINAL, PHENDIMETRAZINE, 
etc.) Potential for abuse less than for drugs in 
Schedule II. Abuse may lead to moderate or low 
physical dependence or high psychological de­
pendence. 
Schedule IV (VALIUM, PHENOBARBITAL, etc.) 
Potential for abuse less than for drugs in Schedule 
III. Abuse may lead to limited physical or.psycho-
Iogical dependence. 
Schedule V (LOMOTIL, CHERACOL SYRUP, 
etc.) Potential for abuse and dependence less than 
for drugs in Schedule IV. 
NAMCS data in table 4 reveal that a small but critical 
proportion (9 percent) of all drug mentions were con-
trolled drugs, of which drugs in Schedule IV enjoyed 
the highest frequency of mention. 
Composition status. –Table 5 reveals that about 
26 percent of all drug mentions were combination 
drugs. An issue of long-standing debate in drug 
utilization concerns the use of drugs in fixed-ratio 
combinations as opposed to single-ingredient drugs. 
Combination drugs usualIy cost more and offer less 
flexibility in dosage adjustment; however, they offer 
more potential convenience to the patient. The 
NAMCS data base permits differentiating single-
ingredient drugs from combination drugs and can 
identify the specific ingredients of the combinations 
if this information is required. 
Therapeutic category. –Table 6 characterizes the 
1980 drug mentions by the chief therapeutic effect 
that each was intended to produce. An obvious pre-
eminence is enjoyed by two therapeutic categories, 
nontropical anti-infectives and central nervous system 
drugs, which together accounted for 32 percent of all 
drug mentions. The preeminence was even stronger 
(37 percent) among the leading 200. 
Inquiries about the NAMCS drug data base or its 
1980 findings may be addressed to: 
Hugo Koch

Ambulatory Care Statistics Branch

Division of Health Care Statistics

National Center for Health Statistics









Phone: (30 1) 436-7132

Symbols 
. . . Data not available 
. . . Category not applicable 
Quantity zero 
0.0 Quantity more than zero but less than 
0.05 
z	 Quantity more than zero but less than 
500 where numbers are rounded to 
thousands 
* Figure does not meet standards of 
reliability or precision 
10 aduancedata 
Technical notes 
Source of data and sample design 
The estimates presented in this report are based 
on data collected during 1980 by the National Center 
for Health Statistics by means of the Survey 
(NAMCS). The target universe of NAMCS comprises 
office visits made by ambulatory patients to non-
Federal physicians who are principally engaged in 
office-based, patient care practice. Visits to physi­
cians practicing in Alaska and Hawaii are excluded 
from the range of NAMCS, as are visits to physicians 
who specialize in anesthesiology, pathology, and 
radiology. 
NAMCS uses a multistage probability sample de-
sign that involves a step-wise sampling of primary 
sampling units (PSU’S), physicians’ practices within 
PSU’S, and patient visits within physicians’ practices. 
For 1980 a sample of 2,959 physicians was selected 
from master files maintained by the American Medi­
cal Association and the American Osteopathic Asso­
ciation. The physician response rate was 77.2 percent. 
Sampled physicians were asked to complete Patient 
Records (figure 1) for a systematic random sample 
of office visits made during a randomly assigned 
weekly reporting period. Telephone contacts were 
excluded. During 1980, responding physicians com­
, pleted 46,081 Patient Records, on which they re-
corded 51,372 drug mentions. Characteristics of the 
physician’s practice, such as primary specialty and 
type of practice, were obtained during an induction 
interview. The National Opinion Research Center, 
under contract to the National Center for Health 
Statistics, was responsible for the survey’s field 
operations. 
For a more detailed discussion of the limitations, 
qualifications, and definitions of the data collected 
by NAMCS, see Vital and Health Statistics, Series 13, 
Number 44. 
Sampling errors and rounding of numbers 
The standard error is a measure of the sampling 
variability that occurs by chance because only a sam­
ple, rather than an entire universe, is surveyed. The 
relative standard error of the estimate is obtained by 
. dividing the standard error by the estimate itself and 
is expressed as a percent of the estimate. Tables I and 
II apply these measurements to drug mentions. 
Estimates have been rounded to the nearest thou-
sand. For this reason detailed figures within tables do 
not always add to totals. Rates and percents were 
calculated from original, unrounded figures and will 
~, 
not necessarily agree precisely with rates or percents 
1 calculated from rounded data. 
Definitions 
An ambulatory patient is an individual seeking 
personal health services who is neither bedridden nor 
currently admitted to any health care institution on 
the premises. 
A physician eligible for NAMCS is a duly licensed 
doctor of medicine or osteopathy currently in office-
based practice whose primary job is caring for ambu­
latory patients. Excluded from NAMCS are: physi­
cians who are hospital based; physicians who spe­
cialize in anesthesiology, pathology, or radiology; 
physicians who are Federally employed; physicians 
who treat only institutionalized patients; physicians 
employed full time by an institution; and physicians 
who spend no time seeing ambulatory patients. 
An office is a place that the physician identifies 
as a location for his ambulatory practice. Responsibil­
ity over time for patient, care and professional serv­
ices rendered there generally resides with the individ­
ual physician rather than an institution. 
A visit is a direct personal exchange between an 
ambulatory patient and a physician or a staff member 
working under the physician’s supervision, for the 
respective purpose of seeking care or rendering health 
services. 
A drug mention is the physician’s entry of a phar­
maceutical agent ordered or provided for prevention, 
diagnosis, or treatment. Generic as well as brand-
name drugs are included, as are nonprescription as 
well as prescription drugs. Along with all new drugs, 
the physician also records continued medications, if 
the patient was specifically instructed during the visit 
to continue the medication. 
Table 1. Approximate relative standard errors of estimated number of 
drug mentions based on all physician specialties: National Ambula­
tory Medical Care Survey, 1980 
RelativeEstimated number of drug mentions 
standardin thousands 
error 
1,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27.3 
2,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19.7 
5,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13.2 
10,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.1 
20,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.2 
50,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6.8 
100,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6.2 
300,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.8 
650,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.8 
Example of use of table: An aggregate estimate of 175,000,000 drug 
mentions has a relative standard arror of 6.5 percent or a standard error 




Table 11. Approximate standard errors of percent of estimated numbers of drug mentions based on all physician specialties: NAMCS, 1980 
Base of percent 
Estimated percent 
(number of drug mentions in thousands) 1 or 99 5 or 95 100r90 20 or 80 30 or 70 50 
Standard error in percentage points 
1,000............................ .4....... 2.7 5.8 8.0 70.7 12.2 13.3 
2,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.9 4.1 5.7 7.6 8.7 9.4 
5,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.2 2.6 3.6 4.8 5.5 6.0 
20,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.6 1.3 1.8 2.4 2.7 3.0 
100,000, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.3 0.6 0.8 1.1 1.2 1.3 
600,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.1 0.2 0.3 0.4 0.5 0.5 
Example of use of teble: An estimate of 30 percent based on an aggregate of 12,500,000 drug mentionswes a standard error of 4.1 percent or e 
relative standard error of 13.7 percent (4.1 percent+ 30 percent). 
12
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